| A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B (NCT05365217) | Novo Nordisk A/S | 2022-05-18 |
| Observatory of Patients With Haemophilia B Treated by IdElvion® (NCT05086575) | CSL Behring | 2021-12-03 |
| Post-marketing Surveillance (Use Result Surveillance) With Refixia® (NCT03875547) | Novo Nordisk A/S | 2019-08-23 |
| A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN (NCT03745924) | Novo Nordisk A/S | 2019-04-01 |
| A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) (NCT03741881) | Novo Nordisk A/S | 2018-12-18 |
| Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B (NCT03276130) | Swedish Orphan Biovitrum | 2018-10-30 |
| Adverse Event Data Collection From External Registries on Nonacog Beta Pegol (NCT03690336) | Novo Nordisk A/S | 2018-10-01 |
| A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia (NCT03660774) | Novo Nordisk A/S | 2018-09-27 |
| A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France (NCT03655340) | Swedish Orphan Biovitrum | 2018-09-12 |
| A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (NCT03055611) | Swedish Orphan Biovitrum | 2017-05-09 |
| A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (NCT03075670) | Novo Nordisk A/S | 2017-03-07 |
| Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (NCT02568202) | Novo Nordisk A/S | 2015-09-01 |
| Thrombin Generation Numerical Models Validation in Haemophilic Case (NCT02300519) | Centre Hospitalier Universitaire de Saint Etienne | 2015-03-01 |
| To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (NCT02241694) | Novo Nordisk A/S | 2014-11-01 |
| A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care (NCT02049099) | Swedish Orphan Biovitrum | 2014-03-01 |
| Project to Update the Study of Congenital Haemophilia in Spain (NCT01959555) | Novo Nordisk A/S | 2014-03-01 |
| Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects (NCT02084810) | Novo Nordisk A/S | 2014-03-01 |
| Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (NCT01988532) | Novo Nordisk A/S | 2013-10-01 |
| A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors (NCT01949792) | Novo Nordisk A/S | 2013-09-01 |
| Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (NCT01467427) | Novo Nordisk A/S | 2012-05-16 |
| Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (NCT01555749) | Novo Nordisk A/S | 2012-03-12 |
| Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (NCT01503567) | Novo Nordisk A/S | 2012-01-01 |
| Survey Evaluating the Psychosocial Effects of Living With Haemophilia (NCT01322620) | Novo Nordisk A/S | 2011-06-03 |
| Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects (NCT01272206) | Novo Nordisk A/S | 2011-01-01 |
| Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients (NCT01288391) | Novo Nordisk A/S | 2011-01-01 |
| Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (NCT01220141) | Novo Nordisk A/S | 2010-11-01 |
| Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (NCT01228669) | Novo Nordisk A/S | 2010-10-25 |
| Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors (NCT01234545) | Novo Nordisk A/S | 2010-10-01 |
| Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B (NCT00956345) | Novo Nordisk A/S | 2009-08-01 |
| A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers (NCT00951873) | Novo Nordisk A/S | 2009-07-01 |
| Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B (NCT00922792) | Novo Nordisk A/S | 2009-06-01 |
| Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy (NCT00638001) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2008-03-01 |
| Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database (NCT00853086) | Novo Nordisk A/S | 2008-01-01 |
| An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery (NCT02250573) | Bio Products Laboratory | 2005-12-01 |
| Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State (NCT01562457) | Novo Nordisk A/S | 2005-11-01 |
| A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years (NCT02263469) | Bio Products Laboratory | 2005-08-01 |
| Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State (NCT01562587) | Novo Nordisk A/S | 2002-09-01 |
| A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery. (NCT02250560) | Bio Products Laboratory | 2000-04-01 |
| A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B (NCT02263456) | Bio Products Laboratory | 1997-07-01 |
| An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients (NCT02231944) | Bio Products Laboratory | 1997-07-01 |